Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/93003
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Emerging evidence on the pathobiology of mucositis
Author: Al-Dasooqi, N.
Sonis, S.
Bowen, J.
Bateman, E.
Blijlevens, N.
Gibson, R.
Logan, R.
Nair, R.
Stringer, A.
Yazbeck, R.
Elad, S.
Lalla, R.
Citation: Supportive Care in Cancer, 2013; 21(11):3233-3241
Publisher: Springer-Verlag
Issue Date: 2013
ISSN: 0941-4355
1433-7339
Statement of
Responsibility: 
Noor Al-Dasooqi, Stephen T. Sonis, Joanne M. Bowen, Emma Bateman, Nicole Blijlevens, Rachel J. Gibson, Richard M. Logan, Raj G. Nair, Andrea M. Stringer, Roger Yazbeck, Sharon Elad, Rajesh V. Lalla, For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, International Society of Oral Oncology (MASCC, ISOO)
Abstract: BACKGROUND: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. METHODS: Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011. RESULTS: Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology. CONCLUSION: The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.
Keywords: Mucosal injury; Cancer therapy; Targeted drugs; Toxicity; Alimentary tract; Pharmacogenetics
Description: An earlier version of this article was published in Volume 21, Issue 7, under DOI 10.​1007/​s00520-013-1810-y
Rights: © Springer-Verlag Berlin Heidelberg 2013
RMID: 0030009453
DOI: 10.1007/s00520-013-1900-x
Appears in Collections:Physiology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.